Als News

I participated in an incredibly well organized and facilitated workshop on Brainstorming Design for Health: Helping Patients Utilize Patient-Generated Data on the Web on Saturday.

Presenting a $270,000 check to Sean Magovern, president of the Joan Dancy and PALS Foundation, at the Woodbridge ShopRite are Richard Saker, president of Saker ShopRites; Rick Saker and Tom Saker, Saker ShopRites vice presidents; and Joe Saker, Saker ShopRites senior vice president.

Fred Noble, who says he has done about everything a human being can do is approaching Lou Gehrig's disease the same way he has approached the rest of his life.

New Video Highlights Aspen's Devotion to ALS Patients /EINPresswire.com/ Lewisville, Texas - February 6, 2012 -- A new video will be released this month featuring former Oakland Raiders running back Steve Smith.

The net loss for the fourth quarter was $11.9 million, or $0.16 per basic and diluted share.

Dr. Richard Olney, one of the nation's top medical researchers who was seeking a cure for Lou Gehrig's disease when he contracted the disease himself eight years ago, died Friday in his Corte Madera home.

Newswise - In the quest to find treatments for certain neurological diseases, BrainStorm is fast distinguishing itself as a leader in the field of regenerative medicine using stem cells through its unique platform called NurOwn.

Iran unveiled 6 new biotechnological medicines Sunday in presence of Iranian President Mahmoud Ahmadinejad.

Street art. Gee-whiz tech. An indomitable human spirit. A commercial director's eye for details.

Tony "Tempt" Quan, a noted Los Angeles artist who is paralyzed by ALS, uses an Eyewriter to help unleash his artistic abilities.

A lot of drug companies have struggled to find their identity as competition and costs collide with profits.

Biomarkers Summit January 16 - 17, 2012 World Companion Diagnostic Summit March 26 - 29,2012 Biomarker World Congress 2012 May 21-23, 2012 New York, USA & Petach Tikvah, Israel, January 17, 2012 / B3C newswire / - BrainStorm Cell Therapeutics Inc.